13F Holdings
中文EN

ARTL ARTELO BIOSCIENCES, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1621221 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY9.4%
TTM EPS YoY188.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-404.2%
ROA-206.9%
ROIC (approx.)-398.3%
Asset turnover—

Leverage & solvency

Liabilities / assets6.6%
Debt / equity0.00x
Current ratio10.47x
Interest coverage-83.52x

Cash quality & payout

Operating cash flow / net income1.04x
Accruals ratio8.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$803,000$876,000$773,000$893,000$1.27M$1.87M$1.38M$2.48M
SG&A expense$989,000$1.63M$1.92M$1.89M$1.81M$1.28M$995,000$1.34M
Operating income-$1.79M-$2.50M-$2.69M-$2.79M-$3.09M-$3.15M-$2.38M-$3.81M
Interest expense$0$6,000$100,000$11,000$111,000$72,000$0$0
Income tax—$0—$0$0$0$0$0
Net income-$1.77M-$2.43M-$2.96M-$4.17M-$3.12M-$3.22M-$2.37M-$3.78M
EPS (diluted)-3.19-0.89-4.00—-88.80-16.86-12.55—
Weighted avg. shares (diluted)554,1972.71M739,000—35,136191,000189,000—
Balance sheet
Cash & equivalents$4,198$4.44M$4.20M$600,000$1.72M$2.07M$746,000$2.34M
Short-term investments————$0$0$0$0
Current assets$4.60M$4.37M$10.42M$695,000$1.83M$2.23M$1.38M$2.56M
Intangibles$2.04M$2.04M$2.04M$2.04M$2.04M$2.04M$2.04M$2.04M
Total assets$6.67M$6.46M$12.52M$2.80M$4.27M$4.36M$3.52M$4.70M
Current liabilities$439,000$1.46M$5.83M$4.04M$4.86M$5.71M$2.80M$1.77M
Total liabilities$439,000$1.46M$5.85M$4.07M$4.90M$5.76M$2.86M$1.84M
Shareholders' equity$6.24M$5.00M$6.67M-$1.27M-$635,000-$1.41M$651,000$2.86M
Shares outstanding937,177673,008673,00874,7791.56M704,4253.28M567,582
Cash flow statement
Operating cash flow-$2.62M-$5.03M-$1.19M-$2.91M-$3.50M-$514,000-$1.60M-$2.57M
Investing cash flow———$188,000-$250,000$0$0$500,000
Financing cash flow$2.86M-$1.06M$10.86M$1.61M$3.44M$1.82M$0$57,000
Stock-based compensation-$354,000$570,000$401,000$368,000$432,000$150,000$192,000$201,000

Free plan shows the latest 8 periods; Pro shows all 56 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.